UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Be aware of common budgeting missteps that undermine goals. This overview highlights pitfalls and how to steer clear of them.
16,042 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Investors weigh Amazon's Zoox-related progress against UPS's strategic shifts while oil volatility stirs the market. ...
Oil's sudden jump rattled macro markets and prompted crypto traders to rethink bitcoin price prediction: just as BTC ...
Amazon returns to the bond market to fund AI infrastructure growth as hyperscalers shift from cash to credit. Analyst...
Investors are weighing the upside of autonomous trucking against cost, timing, and risk. This article breaks down the...
As layoffs linger in tech and startups recalibrate, candidates confront the toughest interview question: why were you...
An ETF-based approach blends residential and mortgage REITs to generate passive income without property management. A...
A leading economist warns that renewed hostilities with Iran could trigger a butterfly effect in global markets, keep...
Capital One faces headwinds, but strategic shifts in risk management, digital growth, and funding could unlock market...
Rising tensions around Iran push energy costs higher and complicate the macro outlook. Analysts warn that stagflation...
This article lays out a grounded three-year path for Tesla, focusing on core EV leadership, software-based autonomy r...
Berkshire Hathaway just sent a bold signal to the market by resuming share buybacks after a long pause. This article ...